Alx Oncology Holdings Inc (ALXO) Unusual Options Activity Today

Checking ALXO unusual options activity helps you spot when traders are making outsized bets on Alx Oncology Holdings Inc before the broader market catches on. Alx Oncology Holdings Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor ALXO unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching ALXO unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking ALXO unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and ALXO unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.

The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Catalysts rarely arrive without a footprint, and ALXO unusual options activity is often where that footprint shows up first. Our scanner tracks Alx Oncology Holdings Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at ALXO unusual options volume on the call side or chasing put sweeps, Alx Oncology Holdings Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.